Original article
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
El uso de secukinumab tras la terapia anti-TNF es mayor de lo esperado por el riesgo de desarrollar enfermedad inflamatoria intestinal?
Fatih Albayraka,
, Mustafa Gürb, Ahmet Karataşb, Süleyman Serdar Kocab, Bünyamin Kısacıkc
Corresponding author
a Department of Internal Medicine, Division of Rheumatology, Dr. Ersin Arslan Training and Research Hospital, Şehitkamil, Gaziantep, Turkey
b Department of Internal Medicine, Division of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey
c Department of Rheumatology, Gaziantep Sanko Hospital, Şehitkamil, Gaziantep, Turkey
Read
560
Timeswas read the article
176
Total PDF
384
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 December | 154 | 15 | 169 |
| 2024 November | 62 | 86 | 148 |
| 2024 October | 87 | 40 | 127 |
| 2024 September | 72 | 33 | 105 |
| 2024 August | 8 | 0 | 8 |
| 2024 June | 1 | 2 | 3 |
